Survivor Plasma: A Hidden Cure for Viral Outbreaks?

Humanity is once again facing viral outbreaks, highlighting the urgent need for effective treatments. Convalescent plasma, a therapy utilizing antibodies from recovered patients, has a history dating back to the 1918 influenza pandemic. During the COVID-19 pandemic, over 600,000 Americans received this treatment, which was instrumental in saving numerous lives.

More recently, convalescent plasma was employed during the 2023 West Nile virus outbreak in Israel, showing encouraging signs of efficacy. While it has been used for hantavirus and Ebola in the past, its effectiveness requires early administration and sufficient antibody levels, which were historically challenging to ensure.

The COVID-19 pandemic provided extensive data, allowing for numerous clinical trials that validated convalescent plasma when used early in disease with potent antibody units. This led to its licensing by the FDA in 2024 for immunosuppressed COVID-19 patients, making it the sole antibody therapy available for them.

Despite its validated success, many medical experts exhibit a perplexing reluctance to embrace convalescent plasma. Arguments against its use, such as difficulties in under-resourced areas or lack of standardization, have been addressed by its successful deployment in over 50 countries and by standardizing antibody amounts.

This therapy, being a public good with no profit motive, relies on donors and public health initiatives, unlike pharmaceutical drugs. Governmental health agencies, like the FDA, play a critical role in its collection, testing, and delivery. While randomized trials are ideal, registries have proven effective for gathering safety and efficacy data, especially for new infectious agents.

Crucially, convalescent plasma functions as an antiviral therapy and must be administered early in the disease course for maximum impact. Studies on COVID-19 indicated that its use in outpatients significantly reduced the likelihood of hospitalization. Public health authorities can now identify survivors, collect their plasma, and analyze antibody content, providing a vital interim therapy until vaccines and new drugs are developed.